Announcements
- Pharming Group announces the placement of €100 million convertible bonds due 2029
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
- Pharming Group announces the 2024 Annual General Meeting of Shareholders
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
- Pharming Group to participate in April investor conferences
- Pharming Group reports fourth quarter and full year 2023 financial results
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14
- Pharming Group to participate in February investor conferences
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.75 |
---|---|
High | 9.75 |
Low | 9.75 |
Bid | 8.30 |
Offer | 9.30 |
Previous close | 10.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 19 2024 07:14 BST.
More ▼